SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.

FDA recall notice · announced August 10, 2022 · Ultra Supplement

Class I FDA/FSIS Class I: reasonable probability that use will cause serious adverse health consequences or death.

The product

SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.

Reason for recall

Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

Notes

Distribution: Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.
Lot/code information: Lot DAP272109, Exp: 4/1/2026
Quantity: 750 cartons
Status: Terminated
Products in this recall event:
- SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9. (D-1350-2022)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.